24 studies found for:    Open Studies | "Measles"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Measles" (24 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Unknown  Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Measles
Intervention: Biological: attenuated measles vaccine
2 Recruiting Additional Measles Vaccine at 4 Months of Age
Condition: Measles Infection
Intervention: Biological: Measles vaccine
3 Unknown  Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors
Condition: Measles
Intervention:
4 Recruiting Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients
Condition: Measles
Intervention: Biological: MMR vaccination
5 Recruiting Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
Conditions: Measles;   Mumps;   Rubella
Intervention: Biological: MMR Vaccine
6 Not yet recruiting Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
7 Recruiting Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™);   Biological: Kinrix®;   Biological: Varivax®
8 Not yet recruiting Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MMR Bio-Manguinhos;   Biological: MMR GlaxoSmithKline
9 Recruiting Trial of Additional Measles Vaccine to Reduce Child Mortality
Condition: Measles Vaccine
Intervention: Biological: Early measles vaccine
10 Recruiting Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.
Condition: Measles Vaccine
Intervention: Biological: Early measles vaccine
11 Unknown  Ontogeny of Measles Immunity in Infants
Condition: Measles
Interventions: Biological: Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous);   Biological: MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)
12 Recruiting Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Conditions: Measles;   Mumps;   Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).;   Biological: Merck & Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live.;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
13 Not yet recruiting Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
Condition: Measles; Mumps; Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
14 Unknown  The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants
Conditions: Immunity;   Measles;   Mumps;   Rubella
Interventions: Dietary Supplement: Probiotics (L.acidophilus and B.lactis);   Dietary Supplement: Cornflor
15 Recruiting Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age
Conditions: Rubella;   Measles;   Mumps
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).;   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine.;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
16 Not yet recruiting A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus
Condition: Multiple Myeloma
Intervention: Drug: MV-NIS
17 Recruiting Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Conditions: Recurrent Malignant Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter;   Other: laboratory biomarker analysis;   Procedure: single photon emission computed tomography;   Procedure: computed tomography
18 Recruiting The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age
Conditions: Mortality;   Vaccines
Intervention: Biological: Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine
19 Recruiting Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: carcinoembryonic antigen-expressing measles virus;   Genetic: fluorescence in situ hybridization;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: needle biopsy;   Procedure: neoadjuvant therapy
20 Recruiting Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: MV-NIS;   Drug: cyclophosphamide;   Other: I-123 prior MV-NIS;   Other: I-123 post MV-NIS;   Drug: Liothyronine

Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results
Indicates status has not been verified in more than two years